Glypican-3/GPC3 Protein, Cynomolgus (HEK293, Fc)

GPC3 is a member of the heparan sulfate proteoglycans (HSPGs), and attaches to the cell surface by a glycosylphosphatidylinositol anchor. GPC3 is overexpressed in hepatocellular carcinoma (HCC) and can be used as a tumor marker for HCC. Membrane GPC3 can interact with several growth factors to promote the binding of growth factors to their receptors. GPC3 can form a complex with Wnt and activates Wnt signaling, leading to the HCC growth. In addition, GPC3 is also involved in the pathogenesis of Simpson-Golabi-Behmel overgrowth syndrome, regulates cell growth, regulates embryonic and fetal development^[1][2][3]. Glypican-3/GPC3 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived Glypican-3/GPC3 protein, expressed by HEK293 , with C-hFc labeled tag.

GPC3 is a member of the heparan sulfate proteoglycans (HSPGs), and attaches to the cell surface by a glycosylphosphatidylinositol anchor. GPC3 is overexpressed in hepatocellular carcinoma (HCC) and can be used as a tumor marker for HCC. GPC3 plays a role in liver carcinogenesis^[1]. Specifically, Membrane GPC3 can interact with several growth factors (eg: Wnt, Hedgehogs, bone morphogenetic factors, and FGF) to promote the binding of growth factors to their receptors. GPC3 can form a complex with Wnt and activates Wnt signaling, leading to the HCC growth^[2].
In addition, GPC3 can regulate cell growth. GPC3 is highly expressed in mesodermal embryonic tissues, and the deletion of the GPC3 gene is involved in the pathogenesis of Simpson-Golabi-Behmel overgrowth syndrome. The interaction of GPC3 with IGF2 can reduce IGF2-mediated growth in vivo, which indicates that GPC3 negatively regulates embryonic and fetal development. Besides, GPC3 is a negative transcriptional regulator and tumor suppressor that inhibits the growth of breast, ovary, and lung cancer cells^[2][3].
GPC3 has a cleavage site between Arg358 and Ser359, and can be cleaved by Furin protease^[2].

Cynomolgus

HEK293

C-hFc

XP_005594665.1 (Q25-H559)

102137748  [NCBI]

Approximately 40 kDa

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.